$10+ targetI agree with the estimate of double digits as a target, and one that is not too far off in the distance.
With FDA approval, and with only a hint of marketing intelligence on Nuvo's part, Pennsaid should make the news all over the US. I am sure that many news casts will cover this story, given the fiasco with Cox-2 inhibitor drugs. If the news casts don;t pick up the story on their own, if I were Nuvo, I would have email addresses to all the news stations across America on hand with an email ready to go and as soon as FDA is announced, press the SEND button.
If anything, the news casts, and hopefully also the news prints, will result in free advertising for the product and the company stock. It will allow the American public with an opportunity to at least (as Celebrex's ads say) ask their doctor about it.
I've waited this long, so I can wait another few months.
There is sooo much short-term upside risk to this stock and IMO, very little or imo, no real short-term downside risk.
Short-term UPSIDE risk - FDA, US Partner, Provincial Formularies, Penecure and finally Nasdaq listing.
Only Major short-term Downside risk - No FDA - which based on the very positive latest long-term Phase III results, coupled with the FDA consultants that have been hired by Nuvo to put together the latest submission, this "should be" a non-issue. I guess that is why the stock is where it is (ie. mid-high $0.40)...the words "should be". Once those words are removed from the equation and replaced with "is", this stock should fly.
Longondmx.